Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst; Torben Plesner; Jacob P. Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C. Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W.C.J. van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa Uhlar; Jianping Wang; A. Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai C. Brun; Paul G. Richardson

doi:10.1056/nejmoa1506348

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lokhorst et al. (2015) studied this question.

synapsesocial.com/papers/69d969832a25b240b7a3c2ca https://doi.org/10.1056/nejmoa1506348

View Full Paper

Ask AI

Bookmark

Share

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Ask about this paper

Abstract

Discussion

Cite This Study

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading